PSMA-based MR Imaging and Therapy of Prostate Cancer

基于 PSMA 的前列腺癌 MR 成像和治疗

基本信息

  • 批准号:
    8490730
  • 负责人:
  • 金额:
    $ 11.6万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-07-01 至 2016-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This project is designed to customize the educational and research activities for Dr. Sangeeta Ray to achieve two major goals. The immediate goal is for Dr. Ray to expand her current research program in the targeted imaging of prostate cancer. Specifically, she will develop a new generation of imaging agents for the prostate- specific membrane antigen (PSMA) that will employ modalities and techniques not previously described. PSMA is an attractive target for the imaging and therapy of cancer in general, as it is over-expressed not only in prostate cancer, but in most solid tumor neovasculature. The long-term goal is for Dr. Ray to acquire advanced biomedical research skills and knowledge that complement her skills as an inorganic chemist. The ultimate goal is for her to develop into an independent, interdisciplinary researcher in the area of cellular and molecular imaging of cancer. She will obtain further, formal training in cancer biology, pharmacology and ethics germane to conducting preclinical and translational research. This program will be heavily weighted toward gaining expertise regarding the biology and pharmacology of imaging - particularly using magnetic resonance (MR)-based approaches under the mentorship of two internationally recognized scientists, Drs. Martin Pomper and Zaver Bhujwalla at Johns Hopkins University. Dr. Ray will develop PSMA-targeted multimodal contrast agents (CAs) followed by evaluation of these compounds through in vitro studies and in vivo MR imaging in relevant animal models. That will allow her to evaluate the in vivo binding specificity and pharmacokinetic profile of lead compounds en route to human studies. The combination of a multimodality imaging platform with therapeutic agents will also be explored for targeted drug delivery. The ABCG2 multi- drug resistance pump has become an important target in efforts to overcome chemotherapy resistance. Target tissue selective silencing of the ABCG2 gene via RNA interference could be a new, nontoxic strategy for treating prostate and other cancers. Accordingly, Dr. Ray will focus on the following specific aims: 1) to develop multimodality low molecular weight CAs that target PSMA. 2) To develop macromolecular CAs that target PSMA. 3) To develop PSMA targeted theranostic agents for PCa. This program will provide an excellent milieu in which the applicant - under close mentorship - can become deeply involved in MR imaging for cancer. Mentorship will be geared more toward biological issues to provide a well-rounded portfolio as she progresses toward independence in biomedical imaging research.
描述(由申请人提供):该项目旨在为Sangeeta Ray博士定制教育和研究活动,以实现两个主要目标。雷博士的近期目标是扩大她目前在前列腺癌靶向成像方面的研究计划。具体来说,她将开发新一代的前列腺特异性膜抗原(PSMA)成像剂,将采用以前没有描述的方式和技术。PSMA通常是癌症成像和治疗的有吸引力的靶标,因为它不仅在前列腺癌中过表达,而且在大多数实体瘤新血管中过表达。雷博士的长期目标是获得先进的生物医学研究技能和知识,以补充她作为无机化学家的技能。她的最终目标是发展成为癌症细胞和分子成像领域的独立跨学科研究人员。她将获得进一步的,在癌症生物学,药理学和伦理学密切相关的进行临床前和转化研究的正式培训。该计划将在约翰霍普金斯大学的两名国际公认的科学家Martin Pomper和Zaver Bhujwalla博士的指导下,重点获得有关成像生物学和药理学的专业知识-特别是使用基于磁共振(MR)的方法。Ray博士将开发PSMA靶向多模态造影剂(CA),然后通过体外研究和相关动物模型的体内MR成像对这些化合物进行评价。这将使她能够评估体内结合特异性和药物动力学特征的先导化合物的路线,以人类研究。多模态成像平台与治疗剂的组合也将被探索用于靶向药物递送。ABCG 2多药耐药泵已成为克服化疗耐药性的重要靶点。通过RNA干扰靶组织选择性沉默ABCG 2基因可能是治疗前列腺癌和其他癌症的一种新的无毒策略。因此,Ray博士将专注于以下具体目标:1)开发靶向PSMA的多模态低分子量CA。2)开发针对PSMA的大分子CA。3)目的:开发PSMA靶向治疗前列腺癌的药物。该计划将提供一个很好的环境,其中申请人-在密切的指导下-可以深入参与癌症的磁共振成像。导师将更多地面向生物学问题,以提供一个全面的投资组合,因为她在生物医学成像研究的独立性的进展。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sangeeta Ray其他文献

Sangeeta Ray的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sangeeta Ray', 18)}}的其他基金

Targeted inhibition of metabolic pathways to enhance radiopharmaceutical therapy
靶向抑制代谢途径以增强放射性药物治疗
  • 批准号:
    10577794
  • 财政年份:
    2022
  • 资助金额:
    $ 11.6万
  • 项目类别:
Targeted inhibition of metabolic pathways to enhance radiopharmaceutical therapy
靶向抑制代谢途径以增强放射性药物治疗
  • 批准号:
    10356588
  • 财政年份:
    2022
  • 资助金额:
    $ 11.6万
  • 项目类别:
PSMA-based MR Imaging and Therapy of Prostate Cancer
基于 PSMA 的前列腺癌 MR 成像和治疗
  • 批准号:
    8294527
  • 财政年份:
    2011
  • 资助金额:
    $ 11.6万
  • 项目类别:
PSMA-based MR Imaging and Therapy of Prostate Cancer
基于 PSMA 的前列腺癌 MR 成像和治疗
  • 批准号:
    8688927
  • 财政年份:
    2011
  • 资助金额:
    $ 11.6万
  • 项目类别:
PSMA-based MR Imaging and Therapy of Prostate Cancer
基于 PSMA 的前列腺癌 MR 成像和治疗
  • 批准号:
    8044425
  • 财政年份:
    2011
  • 资助金额:
    $ 11.6万
  • 项目类别:

相似海外基金

Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 11.6万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
  • 批准号:
    10100360
  • 财政年份:
    2024
  • 资助金额:
    $ 11.6万
  • 项目类别:
    Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
  • 批准号:
    24K04974
  • 财政年份:
    2024
  • 资助金额:
    $ 11.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
  • 批准号:
    23K01686
  • 财政年份:
    2023
  • 资助金额:
    $ 11.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
  • 批准号:
    23K01692
  • 财政年份:
    2023
  • 资助金额:
    $ 11.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
  • 批准号:
    23K01695
  • 财政年份:
    2023
  • 资助金额:
    $ 11.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
  • 批准号:
    23K01713
  • 财政年份:
    2023
  • 资助金额:
    $ 11.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
  • 批准号:
    2312319
  • 财政年份:
    2023
  • 资助金额:
    $ 11.6万
  • 项目类别:
    Standard Grant
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
  • 批准号:
    23K01715
  • 财政年份:
    2023
  • 资助金额:
    $ 11.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
  • 批准号:
    10585388
  • 财政年份:
    2023
  • 资助金额:
    $ 11.6万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了